丁丙诺啡减量方案与阿片类药物过量风险的关联
该研究基于加拿大安大略省关联行政健康数据,纳入5774例接受丁丙诺啡维持治疗至少60天后进行减量的成人,评估减量启动时间、减量速度、剂量递减天数比例和减量持续时间与停药后18个月内致命或非致命阿片类药物过量的关联。结果显示,治疗超过1年再启动减量 vs 1年或更短启动减量的过量发生率为6.73 vs 10.35次/100人年(aHR 0.69,95%CI 0.48-0.997);减量速度≤2 mg/月 vs >4 mg/月的aHR为0.65(95%CI 0.46-0.91),>2至≤4 mg/月 vs >4 mg/月的aHR为0.69(95%CI 0.51-0.93);剂量递减天数≤1.75% vs >3.50%的过量发生率为5.87 vs 13.87次/100人年(aHR 0.64,95%CI 0.43-0.93);减量持续时间与过量风险无显著关联。作者认为这些发现强调了精心规划减量方案的重要性,可能有助于减少阿片类药物相关过量死亡。
要点
- 丁丙诺啡治疗超过1年再启动减量 vs 1年或更短启动减量:过量发生率6.73 vs 10.35次/100人年,aHR 0.69(95%CI 0.48-0.997)。
- 减量速度≤2 mg/月 vs >4 mg/月:aHR 0.65(95%CI 0.46-0.91);>2至≤4 mg/月 vs >4 mg/月:aHR 0.69(95%CI 0.51-0.93)。
- 减量期间剂量递减天数≤1.75% vs >3.50%:过量发生率5.87 vs 13.87次/100人年,aHR 0.64(95%CI 0.43-0.93)。
- 减量持续时间与阿片类药物过量风险无显著关联。
- 作者认为精心规划的减量方案可能有助于减少阿片类药物相关过量死亡。
适用人群与场景
- 加拿大安大略省接受丁丙诺啡维持治疗至少60天后进行减量的成人。
- 新丁丙诺啡治疗 episode 纳入时间为2013年1月1日至2019年1月1日,最长随访至2020年4月30日。
研究设计与关键结果
- 研究类型:基于人群的回顾性队列研究,使用关联行政健康数据,纳入5774例成人;中位(IQR)年龄34(28-44)岁,男性3462例(60.0%)。
- 主要终点:停药后18个月内致命或非致命阿片类药物过量的时间。
- 减量启动时间>1年 vs ≤1年:过量发生率6.73 vs 10.35次/100人年,aHR 0.69(95%CI 0.48-0.997)。
- 减量速度≤2 mg/月 vs >4 mg/月:过量发生率6.95 vs 17.27次/100人年,aHR 0.65(95%CI 0.46-0.91);>2至≤4 mg/月 vs >4 mg/月:过量发生率11.48 vs 17.27次/100人年,aHR 0.69(95%CI 0.51-0.93)。
- 减量期间剂量递减天数≤1.75% vs >3.50%:过量发生率5.87 vs 13.87次/100人年,aHR 0.64(95%CI 0.43-0.93)。
- 减量持续时间与阿片类药物过量风险无显著关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调了精心规划减量方案的重要性,并可能有助于减少阿片类药物相关过量死亡。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Retention in buprenorphine therapy is associated with a lower risk of opioid overdose. Nevertheless, many patients discontinue treatment, and there is limited evidence to guide buprenorphine tapering.
OBJECTIVE: To understand what prescribing characteristics are associated with opioid overdose following buprenorphine taper.
DESIGN, SETTING, AND PARTICIPANTS: This is a population-based, retrospective, cohort study of adults who were maintained on buprenorphine for at least 60 days and underwent a buprenorphine taper. The study was conducted in the Canadian province of Ontario, using linked administrative health data. New buprenorphine treatment episodes were accrued between January 1, 2013, and January 1, 2019, and the maximum follow-up was April 30, 2020. Data analysis was performed from December 2020 to August 2022.
EXPOSURES: The primary exposure of interest was time to taper initiation (≤1 year vs >1 year). Secondary exposures included mean rate of taper, percentage days during which the dose was decreasing, and taper duration.
MAIN OUTCOMES AND MEASURES: The primary outcome measure was time to fatal or nonfatal opioid overdose within 18 months following treatment discontinuation.
RESULTS: Among 5774 individuals, the median (IQR) age at index date was 34 (28-44) years, and 3462 individuals (60.0%) were male. Time to taper initiation longer than 1 year vs 1 year or less (6.73 vs 10.35 overdoses per 100 person-years; adjusted hazard ratio [aHR], 0.69; 95% CI, 0.48-0.997), a lower mean rate of taper (≤2 mg per month, 6.95 overdoses per 100 person-years; >2 to ≤4 mg per month, 11.48 overdoses per 100 person-years; >4 mg per month, 17.27 overdoses per 100 person-years; ≤2 mg per month vs >4 mg per month, aHR, 0.65; 95% CI, 0.46-0.91; >2 to ≤4 mg per month vs >4 mg per month, aHR, 0.69; 95% CI, 0.51-0.93), and dose decreases in 1.75% or less of days vs more than 3.50% of days during the taper period (5.87 vs 13.87 overdoses per 100 person-years; aHR, 0.64; 95% CI, 0.43-0.93) were associated with reduced risk of opioid overdose; however, taper duration was not.
CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, buprenorphine tapers undertaken after at least 1 year of therapy, a slower rate of taper, and a lower percentage of days during which the dose was decreasing were associated with a significantly lower risk of opioid overdose, regardless of taper duration. These findings underscore the importance of a carefully planned taper and could contribute to reduction in opioid-related overdose death.
参考来源
- Bozinoff N, Men S, Kurdyak P, et al. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper. JAMA Netw Open. 2022. PMID: 36173629. doi:10.1001/jamanetworkopen.2022.34168
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。